The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SRDX | -26.88% | -25.35% | -5.67% | +575% |
| S&P | +19.89% | +109.18% | +15.89% | +553% |
Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.
The company gained FDA marketing approval for a drug-coated balloon that will help clear blocked arteries.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $29.57M | -2.6% |
| Gross Profit | $20.08M | -4.5% |
| Gross Margin | 67.92% | -1.4% |
| Market Cap | $424.83M | -29.1% |
| Market Cap / Employee | $1.09M | 0.0% |
| Employees | 389 | 0.0% |
| Net Income | -$5.32M | 29.6% |
| EBITDA | $4.06M | 1284.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $26.28M | 8.1% |
| Accounts Receivable | $22.51M | -3.9% |
| Inventory | 15.8 | 2.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $31.56M | -2.7% |
| Short Term Debt | $1.02M | 0.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -10.15% | -9.4% |
| Return On Invested Capital | -5.83% | -2.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $0.90M | 130.2% |
| Operating Free Cash Flow | $1.41M | 169.1% |
| Metric | Q4 2023 | Q1 2024 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 93.66 | 30.67 | - | ||
| Price to Book | 4.68 | 4.77 | 3.90 | 3.85 | -20.33% |
| Price to Sales | 4.36 | 4.49 | 3.59 | 3.51 | -28.76% |
| Price to Tangible Book Value | 10.83 | 11.19 | 9.07 | 9.34 | -13.42% |
| Price to Free Cash Flow TTM | 51.97 | 18.45 | - | ||
| Enterprise Value to EBITDA | 228.12 | 297.81 | 695.66 | 104.44 | -106.06% |
| Free Cash Flow Yield | 1.9% | 5.4% | - | ||
| Return on Equity | -9.7% | -12.3% | -17.0% | -15.4% | 1166.03% |
| Total Debt | $33.24M | $33.03M | $32.81M | $32.58M | -2.60% |
SRDX earnings call for the period ending September 30, 2021.
SRDX earnings call for the period ending June 30, 2021.
SRDX earnings call for the period ending March 31, 2021.
SRDX earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
